Roth Capital analyst Debjit Chattopadhyay reiterated a Buy and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $45.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE